Cargando…

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

OBJECTIVES: We prospectively compared the preventive effects of rosuvastatin and atorvastatin on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI). METHODS: We enrolled 1078 consecutive patients with CKD undergoing el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yong, Liu, Yuan-hui, Tan, Ning, Chen, Ji-yan, Zhou, Ying-ling, Li, Li-wen, Duan, Chong-yang, Chen, Ping-Yan, Luo, Jian-fang, Li, Hua-long, Wei-Guo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214705/ https://www.ncbi.nlm.nih.gov/pubmed/25357250 http://dx.doi.org/10.1371/journal.pone.0111124

Ejemplares similares

Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention
por: Firouzi, Ata, et al.
Publicado: (2018)

Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy
por: Yun, Kyeong Ho, et al.
Publicado: (2014)

Safe Contrast Volumes for Preventing Contrast-Induced Nephropathy in Elderly Patients With Relatively Normal Renal Function During Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2015)

Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin
por: Golshani, Samad, et al.
Publicado: (2022)

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
por: Shoukat, Sana, et al.
Publicado: (2010)

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
por: Bidram, Peyman, et al.
Publicado: (2015)

Comparison of the Treatment Efficacy of Rosuvastatin versus Atorvastatin Loading Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
por: Adel, Esraa M., et al.
Publicado: (2022)

Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions
por: Li, Wen-hua, et al.
Publicado: (2012)

Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography
por: Bei, Wei-Jie, et al.
Publicado: (2017)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction
por: Zhou, Langping, et al.
Publicado: (2023)

Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Yang, Rong, et al.
Publicado: (2014)

Effects of Serum Cytochrome c on Contrast-Induced Nephropathy in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
por: Tang, Chengchun, et al.
Publicado: (2019)

Association between Serum Ferritin and Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Zhu, Boqian, et al.
Publicado: (2016)

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
por: Khurana, Sushant, et al.
Publicado: (2015)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Evaluation of efficacy and safety of combined rosuvastatin and atorvastatin in treating with coronary heart disease: A protocol for systematic review and meta-analysis
por: Li, Ke, et al.
Publicado: (2021)

Urinary interleukin-18 as an early indicator to predict contrast-induced nephropathy in patients undergoing percutaneous coronary intervention
por: HE, HAIYAN, et al.
Publicado: (2014)

Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2018)

Percutaneous coronary intervention for chronic total occlusion improved prognosis in patients with renal insufficiency at high risk of contrast-induced nephropathy
por: Liu, Yong, et al.
Publicado: (2016)

Increased urinary adiponectin level is associated with contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention
por: Zhang, Jun-yi, et al.
Publicado: (2019)

Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
por: Lee, Yong-Joon, et al.
Publicado: (2023)

Relationship Between the Urine Flow Rate and Risk of Contrast-Induced Nephropathy After Emergent Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2015)

Risk factors of contrast-induced nephropathy in patients with STEMI and pump failure undergoing percutaneous coronary intervention
por: Chen, Hongwu, et al.
Publicado: (2021)

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia
por: Vahit, Demir, et al.
Publicado: (2018)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Intensity of hydration changes the role of renin–angiotensin–aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease
por: Guo, Xiao-sheng, et al.
Publicado: (2017)

Predictive value of preprocedural albuminuria for contrast-induced nephropathy non-recovery in patients undergoing percutaneous coronary intervention
por: Chen, Hanchuan, et al.
Publicado: (2021)

Fibrinogen-to-Albumin Ratio Predicts Contrast-Induced Nephropathy in Patients after Emergency Percutaneous Coronary Intervention
por: You, Zhebin, et al.
Publicado: (2019)

Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India
por: Roy, Debabrata, et al.
Publicado: (2020)

The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study
por: Ma, Huan, et al.
Publicado: (2017)

Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial
por: Liu, Jinming, et al.
Publicado: (2016)

Statistical analysis plan for aggressive hydraTion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT) study
por: Liu, Jin, et al.
Publicado: (2020)

In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
por: Galani, VJ, et al.
Publicado: (2010)

Glycemic variability as predictor of contrast-induced nephropathy in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention
por: Zuo, Pengfei, et al.
Publicado: (2020)

Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
por: Zhang, H., et al.
Publicado: (2021)

Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients
por: Tian, Jianwei, et al.
Publicado: (2016)

Urinary semaphorin 3A as an early biomarker to predict contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention
por: Ning, Li, et al.
Publicado: (2018)

Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography
por: Sanei, Hamid, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_malad1ft3hbbbevmi4o6eb7qta